Nutritional Regulation of Wound Inflammation: Part III

NCT ID: NCT02332993

Last Updated: 2019-07-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

22 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-12-31

Study Completion Date

2018-02-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine the changes that result in the wound healing of a type II Diabetic using Negative Pressure Therapy after 12 weeks of daily supplementation of ImmunAge (Fermented Papaya Preparation (FPP). ImmunAge (FPP) is a supplement made from Carica papaya Linn and is available over the counter. ImmunAge (FPP) is an investigational drug, which means it has not been approved by the U. S. Food and Drug Administration (FDA). Approximately 30 subjects will participate in this study. 15 subjects will take the supplementation and 15 subjects to take no supplementation as the control. The

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There are a total of 3 study visits over the course of the 12 weeks of the study that will include procedures such as collection of their wound dressing, imaging, blood draw, and receiving the supplement (if in supplementation group). These visits will occur at weeks 0 (consent signed and first distribution of supplements), 2, 3, and 12. At the initial visit the following will be recorded: birth year, gender, ethnicity, race, women of child bearing age: current form of birth control, negative or positive urine Hcg, current medications (medication, dose, frequency, diagnosis), allergies, past or present medical problems, height and weight, HbA1c value, wound site, wound etiology, Blood pressure, pulse, and if the subjects will be randomized into either the control or supplementation group. Subjects will return one week later for study visit one where their blood pressure and pulse will be recorded and will also have one of the following tests completed as a screen fail for the study: Transcutaneous Oxygen Measurement, Toe Pressure, or Ankle-Brachial Index Test. If the reading is inadequate then the subject will no longer participate in the study. Their wound vac sponge will be collected and imaging will be obtained. Subjects will return for study visit 2 where they will have their blood pressure and pulse recorded, will have a blood draw, wound vac sponge collected and wound imaging obtained. Subjects will be asked to return after 12 weeks of supplementation and will have their blood pressure and pulse recorded and wound imaging obtained. Subjects will be asked to bring any empty packets of the supplement to each visit for compliance and will be given a new supply of supplements at the initial visit, visit 1 and 2. Note, if a subject is discontinued from the negative pressure therapy within 2 weeks of consent then the subject will be dropped from the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Negative Pressure Therapy Wound Open Wound Type II Obese Diabetic Type II Non-Obese Diabetic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Supplementation Group

15 Type 2 Diabetics receiving Negative Wound Pressure Therapy will receive the FPP supplementation to take 3 times a day for 12 weeks (3g/dose).

FPP

Intervention Type DIETARY_SUPPLEMENT

Made from Carica papaya and represents a sweet and granular substance available over the counter. FPP possesses antioxidant properties that can provide benefit against age-related complications..

Control Group

15 Type 2 Diabetics receiving Negative Wound Pressure Therapy will receive no supplementation for 12 weeks.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FPP

Made from Carica papaya and represents a sweet and granular substance available over the counter. FPP possesses antioxidant properties that can provide benefit against age-related complications..

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fermented Papaya Preparation Immun'Age Osato

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients 30 - 70 years
* Patient must understand and give written informed consent
* Patient must be a Type II Diabetic
* HbA1c ≤9%
* Receiving Negative Pressure Therapy (NPWT)

One or more of the following:

* Transcutaneous Oxygen Measurement \>30 mmHg
* ABI (Ankle-Brachial Index) \>0.7 and less 1.3
* Toe Pressures \>30 mmHg

Exclusion Criteria

* Individuals who are deemed unable to understand the procedures, risks and benefits of the study, i.e. Informed consent will be excluded.
* Patients who are pregnant (all women of childbearing age will have a urine Hcg test upon enrollment and agree upon one of the following forms of contraception for the duration of the study: Abstinence, Hormonal contraception, spermicidal condoms, or either you or your partner having been surgically sterilized)
* Immuno-compromised patients; receiving radiation therapy, chemo, or have gone through transplantation or other conditions with prolonged steroid use
* Patients with clinical signs of soft tissue infection such as fever, erythema, leukocytosis, purulent drainage.
* Antibiotic use 7 days prior to biopsy and cultures
* Current smoker
* Clinically significant kidney or liver disease (dialysis)
* Severe neurologic dysfunction

Females who are pregnant as well as individuals who are therapeutically immuno-compromised will also be excluded in order to minimize the risk to such individuals (and fetus) and to decrease statistical variability and to minimize potential of confounders.
Minimum Eligible Age

30 Years

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Osato Research Institute

OTHER

Sponsor Role collaborator

Ohio State University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sashwati Roy, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Ohio State University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University East Hospital

Columbus, Ohio, United States

Site Status

Martha Morehouse Medical Plaza

Columbus, Ohio, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Nayak SB, Pinto Pereira L, Maharaj D. Wound healing activity of Carica papaya L. in experimentally induced diabetic rats. Indian J Exp Biol. 2007 Aug;45(8):739-43.

Reference Type RESULT
PMID: 17877152 (View on PubMed)

Pieper B, Caliri MH. Nontraditional wound care: A review of the evidence for the use of sugar, papaya/papain, and fatty acids. J Wound Ostomy Continence Nurs. 2003 Jul;30(4):175-83. doi: 10.1067/mjw.2003.131.

Reference Type RESULT
PMID: 12851592 (View on PubMed)

Babior BM. The enzymatic basis for O-.2 production by human neutrophils. Can J Physiol Pharmacol. 1982 Nov;60(11):1353-8. doi: 10.1139/y82-202.

Reference Type BACKGROUND
PMID: 6295574 (View on PubMed)

Wheat LJ. Infection and diabetes mellitus. Diabetes Care. 1980 Jan-Feb;3(1):187-97. doi: 10.2337/diacare.3.1.187.

Reference Type RESULT
PMID: 6996964 (View on PubMed)

Carton JA, Maradona JA, Nuno FJ, Fernandez-Alvarez R, Perez-Gonzalez F, Asensi V. Diabetes mellitus and bacteraemia: a comparative study between diabetic and non-diabetic patients. Eur J Med. 1992 Sep;1(5):281-7.

Reference Type RESULT
PMID: 1341610 (View on PubMed)

Bagdade JD, Root RK, Bulger RJ. Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes. 1974 Jan;23(1):9-15. doi: 10.2337/diab.23.1.9. No abstract available.

Reference Type RESULT
PMID: 4809622 (View on PubMed)

Bagdade JD, Nielson KL, Bulger RJ. Reversible abnormalities in phagocytic function in poorly controlled diabetic patients. Am J Med Sci. 1972 Jun;263(6):451-6. doi: 10.1097/00000441-197206000-00005. No abstract available.

Reference Type RESULT
PMID: 4403194 (View on PubMed)

Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol. 1999 Dec;26(3-4):259-65. doi: 10.1111/j.1574-695X.1999.tb01397.x.

Reference Type RESULT
PMID: 10575137 (View on PubMed)

Babior BM. Oxygen-dependent microbial killing by phagocytes (first of two parts). N Engl J Med. 1978 Mar 23;298(12):659-68. doi: 10.1056/NEJM197803232981205. No abstract available.

Reference Type RESULT
PMID: 24176 (View on PubMed)

Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, Nicotera T. Oxidative damage to DNA in diabetes mellitus. Lancet. 1996 Feb 17;347(8999):444-5. doi: 10.1016/s0140-6736(96)90013-6.

Reference Type RESULT
PMID: 8618487 (View on PubMed)

Chang FY, Shaio MF. Respiratory burst activity of monocytes from patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1995 Aug;29(2):121-7. doi: 10.1016/0168-8227(95)01123-4.

Reference Type RESULT
PMID: 8591699 (View on PubMed)

Anuar NS, Zahari SS, Taib IA, Rahman MT. Effect of green and ripe Carica papaya epicarp extracts on wound healing and during pregnancy. Food Chem Toxicol. 2008 Jul;46(7):2384-9. doi: 10.1016/j.fct.2008.03.025. Epub 2008 Apr 3.

Reference Type RESULT
PMID: 18468758 (View on PubMed)

Nau JY. [The Pope and the enlightenment of fermented papaya]. Rev Med Suisse. 2005 Feb 9;1(6):459. No abstract available. French.

Reference Type RESULT
PMID: 15786653 (View on PubMed)

Imao K, Wang H, Komatsu M, Hiramatsu M. Free radical scavenging activity of fermented papaya preparation and its effect on lipid peroxide level and superoxide dismutase activity in iron-induced epileptic foci of rats. Biochem Mol Biol Int. 1998 Jun;45(1):11-23. doi: 10.1080/15216549800202392.

Reference Type RESULT
PMID: 9635126 (View on PubMed)

Rimbach G, Park YC, Guo Q, Moini H, Qureshi N, Saliou C, Takayama K, Virgili F, Packer L. Nitric oxide synthesis and TNF-alpha secretion in RAW 264.7 macrophages: mode of action of a fermented papaya preparation. Life Sci. 2000 Jun 30;67(6):679-94. doi: 10.1016/s0024-3205(00)00664-0.

Reference Type RESULT
PMID: 12659174 (View on PubMed)

Marotta F, Barreto R, Tajiri H, Bertuccelli J, Safran P, Yoshida C, Fesce E. The aging/precancerous gastric mucosa: a pilot nutraceutical trial. Ann N Y Acad Sci. 2004 Jun;1019:195-9. doi: 10.1196/annals.1297.031.

Reference Type RESULT
PMID: 15247013 (View on PubMed)

Aruoma OI, Colognato R, Fontana I, Gartlon J, Migliore L, Koike K, Coecke S, Lamy E, Mersch-Sundermann V, Laurenza I, Benzi L, Yoshino F, Kobayashi K, Lee MC. Molecular effects of fermented papaya preparation on oxidative damage, MAP Kinase activation and modulation of the benzo[a]pyrene mediated genotoxicity. Biofactors. 2006;26(2):147-59. doi: 10.1002/biof.5520260205.

Reference Type RESULT
PMID: 16823100 (View on PubMed)

Calzuola I, Gianfranceschi GL, Marsili V. Comparative activity of antioxidants from wheat sprouts, Morinda citrifolia, fermented papaya and white tea. Int J Food Sci Nutr. 2006 May-Jun;57(3-4):168-77. doi: 10.1080/09637480600658328.

Reference Type RESULT
PMID: 17127467 (View on PubMed)

Marotta F, Pavasuthipaisit K, Yoshida C, Albergati F, Marandola P. Relationship between aging and susceptibility of erythrocytes to oxidative damage: in view of nutraceutical interventions. Rejuvenation Res. 2006 Summer;9(2):227-30. doi: 10.1089/rej.2006.9.227.

Reference Type RESULT
PMID: 16706649 (View on PubMed)

Marotta F, Weksler M, Naito Y, Yoshida C, Yoshioka M, Marandola P. Nutraceutical supplementation: effect of a fermented papaya preparation on redox status and DNA damage in healthy elderly individuals and relationship with GSTM1 genotype: a randomized, placebo-controlled, cross-over study. Ann N Y Acad Sci. 2006 May;1067:400-7. doi: 10.1196/annals.1354.057.

Reference Type RESULT
PMID: 16804018 (View on PubMed)

Amer J, Goldfarb A, Rachmilewitz EA, Fibach E. Fermented papaya preparation as redox regulator in blood cells of beta-thalassemic mice and patients. Phytother Res. 2008 Jun;22(6):820-8. doi: 10.1002/ptr.2379.

Reference Type RESULT
PMID: 18384199 (View on PubMed)

Dawkins G, Hewitt H, Wint Y, Obiefuna PC, Wint B. Antibacterial effects of Carica papaya fruit on common wound organisms. West Indian Med J. 2003 Dec;52(4):290-2.

Reference Type RESULT
PMID: 15040064 (View on PubMed)

Gurung S, Skalko-Basnet N. Wound healing properties of Carica papaya latex: in vivo evaluation in mice burn model. J Ethnopharmacol. 2009 Jan 21;121(2):338-41. doi: 10.1016/j.jep.2008.10.030. Epub 2008 Nov 8.

Reference Type RESULT
PMID: 19041705 (View on PubMed)

Mikhal'chik EV, Ivanova AV, Anurov MV, Titkova SM, Pen'kov LY, Kharaeva ZF, Korkina LG. Wound-healing effect of papaya-based preparation in experimental thermal trauma. Bull Exp Biol Med. 2004 Jun;137(6):560-2. doi: 10.1023/b:bebm.0000042711.31775.f7.

Reference Type RESULT
PMID: 15455084 (View on PubMed)

Khanna S, Biswas S, Shang Y, Collard E, Azad A, Kauh C, Bhasker V, Gordillo GM, Sen CK, Roy S. Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PLoS One. 2010 Mar 4;5(3):e9539. doi: 10.1371/journal.pone.0009539.

Reference Type RESULT
PMID: 20209061 (View on PubMed)

Collard E, Roy S. Improved function of diabetic wound-site macrophages and accelerated wound closure in response to oral supplementation of a fermented papaya preparation. Antioxid Redox Signal. 2010 Sep 1;13(5):599-606. doi: 10.1089/ars.2009.3039.

Reference Type RESULT
PMID: 20095880 (View on PubMed)

Marotta F, Koike K, Lorenzetti A, Naito Y, Fayet F, Shimizu H, Marandola P. Nutraceutical strategy in aging: targeting heat shock protein and inflammatory profile through understanding interleukin-6 polymorphism. Ann N Y Acad Sci. 2007 Nov;1119:196-202. doi: 10.1196/annals.1404.011.

Reference Type RESULT
PMID: 18056967 (View on PubMed)

Thiele JJ, Traber MG, Packer L. Depletion of human stratum corneum vitamin E: an early and sensitive in vivo marker of UV induced photo-oxidation. J Invest Dermatol. 1998 May;110(5):756-61. doi: 10.1046/j.1523-1747.1998.00169.x.

Reference Type RESULT
PMID: 9579541 (View on PubMed)

Das A, Dickerson R, Ghatak PD, Gordillo GM, Chaffee S, Saha A, Khanna S, Roy S. May Dietary Supplementation Augment Respiratory Burst in Wound-Site Inflammatory Cells? Antioxid Redox Signal. 2018 Feb 10;28(5):401-405. doi: 10.1089/ars.2017.7304. Epub 2017 Oct 16.

Reference Type DERIVED
PMID: 28810801 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20141371

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Treatment of PRP on Diabetes Wound
NCT02088268 COMPLETED NA